If this message does not display properly, please click here to launch your browser.
|
Based on our Pharmacor advisory service entitled Venous Thromboembolism, Decision Resources is offering an exclusive analyst call entitled Landmark Findings from the European Society of Cardiology Congress - Assessing Xarelto’s Potential to Streamline the Treatment of VTE. Because this presentation will feature major updates, it is ONLY available to purchasers of this Pharmacor advisory service. Please contact us to learn how you can purchase this Pharmacor advisory service and attend the analyst call. The treatment of VTE will be revolutionized by novel oral anticoagulants that offer effective, safe and more convenient alternatives to current parenteral therapies and warfarin. New data from the Phase III EINSTEIN-DVT clinical trial for the treatment of acute venous thromboembolism (VTE) demonstrated that Johnson & Johnson/Bayer’s oral therapy Xarelto (rivaroxaban) provides similar levels of efficacy and safety compared to the current standard of care—Sanofi-Aventis’s Lovenox (enoxaparin) and warfarin. These landmark findings were presented at the recent European Society of Cardiology Congress. This 15-minute analyst call, presented by Decision Resources Analyst Matthew Killeen, Ph.D., will answer the following questions:
Dr. Killeen will conduct a live Q & A session after the presentation. Registration Landmark Findings from the European Society of Cardiology Congress - Assessing Xarelto’s Potential to Streamline the Treatment of VTE September 10, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris). To learn how you can purchase this Pharmacor advisory service and attend the analyst call, please contact us using the information below. In North America — Keith Rourke at 781-993-2656 or krourke@dresources.com |
|
||||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||||
Matthew Killeen, Ph.D., is an analyst on the cardiovascular and metabolic disorders team at Decision Resources. Prior to joining the company, Dr. Killeen worked in life sciences business development for the London Technology Network and in neuroscience drug discovery at Eli Lilly. He has also held research fellowships at Harvard Medical School and the Massachusetts General Hospital, where he studied the genetic basis of sudden cardiac death. Dr. Killeen is the author of 19 peer-reviewed journal articles on topics including sudden cardiac death, atrial fibrillation, cardiac drug safety and mechanisms underlying cardiac arrhythmias. Dr. Killeen holds a Ph.D. in Cardiac Electrophysiology from Cambridge University and a B.Sc. (first class) in Pharmacology from the University of Leeds.